BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Sensys Medical
Sensys developed a non-invasive blood glucose monitor that used near infrared diffuse reflectance spectroscopy. The technology was designed to provide a painless method to collect data for proactive use in controlling diabetes.
Sensys Medical
Chandler, AZ
